Research ArticleAccepted Article
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Patients Treated with Tofacitinib or Adalimumab
Désirée van der Heijde, Dafna D. Gladman, Oliver FitzGerald, Arthur Kavanaugh, Daniela Graham, Cunshan Wang and Lara Fallon
The Journal of Rheumatology March 2019, jrheum.180971; DOI: https://doi.org/10.3899/jrheum.180971
Désirée van der Heijde
From the Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; Department of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St Vincent’s University Hospital, Dublin, Ireland; Division of Rheumatology, Allergy, and Immunology, University of California, San Diego School of Medicine, La Jolla, San Diego, California, USA; Pfizer Inc, Groton, Connecticut, USA; Pfizer Inc, Montreal, QC, Canada. This study was funded by Pfizer Inc. DvdH has received consultancy fees from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi, Takeda, and UCB; and is the Director of Imaging Rheumatology BV. DDG has received research grants and consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB; and has received consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. OF has received research grants and consultancy fees from AbbVie, Bristol- Myers Squibb, Novartis, and Pfizer Inc; and has received consultancy fees from Amgen, Celgene, Eli Lilly, and Janssen. AK has received consultancy fees or other remuneration from Pfizer Inc. DG, CW, and LF are employees and shareholders of Pfizer Inc. Pfizer Inc were involved in the design of the study, collection, analysis, and interpretation of data, and review and approval of the manuscript. Address correspondence to: Professor Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: mail@dvanderheijde.nl.
Dafna D. Gladman
From the Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; Department of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St Vincent’s University Hospital, Dublin, Ireland; Division of Rheumatology, Allergy, and Immunology, University of California, San Diego School of Medicine, La Jolla, San Diego, California, USA; Pfizer Inc, Groton, Connecticut, USA; Pfizer Inc, Montreal, QC, Canada. This study was funded by Pfizer Inc. DvdH has received consultancy fees from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi, Takeda, and UCB; and is the Director of Imaging Rheumatology BV. DDG has received research grants and consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB; and has received consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. OF has received research grants and consultancy fees from AbbVie, Bristol- Myers Squibb, Novartis, and Pfizer Inc; and has received consultancy fees from Amgen, Celgene, Eli Lilly, and Janssen. AK has received consultancy fees or other remuneration from Pfizer Inc. DG, CW, and LF are employees and shareholders of Pfizer Inc. Pfizer Inc were involved in the design of the study, collection, analysis, and interpretation of data, and review and approval of the manuscript. Address correspondence to: Professor Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: mail@dvanderheijde.nl.
Oliver FitzGerald
From the Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; Department of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St Vincent’s University Hospital, Dublin, Ireland; Division of Rheumatology, Allergy, and Immunology, University of California, San Diego School of Medicine, La Jolla, San Diego, California, USA; Pfizer Inc, Groton, Connecticut, USA; Pfizer Inc, Montreal, QC, Canada. This study was funded by Pfizer Inc. DvdH has received consultancy fees from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi, Takeda, and UCB; and is the Director of Imaging Rheumatology BV. DDG has received research grants and consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB; and has received consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. OF has received research grants and consultancy fees from AbbVie, Bristol- Myers Squibb, Novartis, and Pfizer Inc; and has received consultancy fees from Amgen, Celgene, Eli Lilly, and Janssen. AK has received consultancy fees or other remuneration from Pfizer Inc. DG, CW, and LF are employees and shareholders of Pfizer Inc. Pfizer Inc were involved in the design of the study, collection, analysis, and interpretation of data, and review and approval of the manuscript. Address correspondence to: Professor Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: mail@dvanderheijde.nl.
Arthur Kavanaugh
From the Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; Department of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St Vincent’s University Hospital, Dublin, Ireland; Division of Rheumatology, Allergy, and Immunology, University of California, San Diego School of Medicine, La Jolla, San Diego, California, USA; Pfizer Inc, Groton, Connecticut, USA; Pfizer Inc, Montreal, QC, Canada. This study was funded by Pfizer Inc. DvdH has received consultancy fees from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi, Takeda, and UCB; and is the Director of Imaging Rheumatology BV. DDG has received research grants and consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB; and has received consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. OF has received research grants and consultancy fees from AbbVie, Bristol- Myers Squibb, Novartis, and Pfizer Inc; and has received consultancy fees from Amgen, Celgene, Eli Lilly, and Janssen. AK has received consultancy fees or other remuneration from Pfizer Inc. DG, CW, and LF are employees and shareholders of Pfizer Inc. Pfizer Inc were involved in the design of the study, collection, analysis, and interpretation of data, and review and approval of the manuscript. Address correspondence to: Professor Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: mail@dvanderheijde.nl.
Daniela Graham
From the Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; Department of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St Vincent’s University Hospital, Dublin, Ireland; Division of Rheumatology, Allergy, and Immunology, University of California, San Diego School of Medicine, La Jolla, San Diego, California, USA; Pfizer Inc, Groton, Connecticut, USA; Pfizer Inc, Montreal, QC, Canada. This study was funded by Pfizer Inc. DvdH has received consultancy fees from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi, Takeda, and UCB; and is the Director of Imaging Rheumatology BV. DDG has received research grants and consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB; and has received consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. OF has received research grants and consultancy fees from AbbVie, Bristol- Myers Squibb, Novartis, and Pfizer Inc; and has received consultancy fees from Amgen, Celgene, Eli Lilly, and Janssen. AK has received consultancy fees or other remuneration from Pfizer Inc. DG, CW, and LF are employees and shareholders of Pfizer Inc. Pfizer Inc were involved in the design of the study, collection, analysis, and interpretation of data, and review and approval of the manuscript. Address correspondence to: Professor Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: mail@dvanderheijde.nl.
Cunshan Wang
From the Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; Department of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St Vincent’s University Hospital, Dublin, Ireland; Division of Rheumatology, Allergy, and Immunology, University of California, San Diego School of Medicine, La Jolla, San Diego, California, USA; Pfizer Inc, Groton, Connecticut, USA; Pfizer Inc, Montreal, QC, Canada. This study was funded by Pfizer Inc. DvdH has received consultancy fees from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi, Takeda, and UCB; and is the Director of Imaging Rheumatology BV. DDG has received research grants and consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB; and has received consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. OF has received research grants and consultancy fees from AbbVie, Bristol- Myers Squibb, Novartis, and Pfizer Inc; and has received consultancy fees from Amgen, Celgene, Eli Lilly, and Janssen. AK has received consultancy fees or other remuneration from Pfizer Inc. DG, CW, and LF are employees and shareholders of Pfizer Inc. Pfizer Inc were involved in the design of the study, collection, analysis, and interpretation of data, and review and approval of the manuscript. Address correspondence to: Professor Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: mail@dvanderheijde.nl.
Lara Fallon
From the Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; Department of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St Vincent’s University Hospital, Dublin, Ireland; Division of Rheumatology, Allergy, and Immunology, University of California, San Diego School of Medicine, La Jolla, San Diego, California, USA; Pfizer Inc, Groton, Connecticut, USA; Pfizer Inc, Montreal, QC, Canada. This study was funded by Pfizer Inc. DvdH has received consultancy fees from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi, Takeda, and UCB; and is the Director of Imaging Rheumatology BV. DDG has received research grants and consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB; and has received consultancy fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. OF has received research grants and consultancy fees from AbbVie, Bristol- Myers Squibb, Novartis, and Pfizer Inc; and has received consultancy fees from Amgen, Celgene, Eli Lilly, and Janssen. AK has received consultancy fees or other remuneration from Pfizer Inc. DG, CW, and LF are employees and shareholders of Pfizer Inc. Pfizer Inc were involved in the design of the study, collection, analysis, and interpretation of data, and review and approval of the manuscript. Address correspondence to: Professor Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: mail@dvanderheijde.nl.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Patients Treated with Tofacitinib or Adalimumab
Désirée van der Heijde, Dafna D. Gladman, Oliver FitzGerald, Arthur Kavanaugh, Daniela Graham, Cunshan Wang, Lara Fallon
The Journal of Rheumatology Mar 2019, jrheum.180971; DOI: 10.3899/jrheum.180971
Accepted manuscript
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Patients Treated with Tofacitinib or Adalimumab
Désirée van der Heijde, Dafna D. Gladman, Oliver FitzGerald, Arthur Kavanaugh, Daniela Graham, Cunshan Wang, Lara Fallon
The Journal of Rheumatology Mar 2019, jrheum.180971; DOI: 10.3899/jrheum.180971